Interleukin-6 inhibits apoptosis of exocrine gland tissues under inflammatory conditions

Cytokine

Volumn 76, Issue 2, 2015, Pages 244-252

  Zhou, Jing ^a,b   Jin, Jun O ^a,c   Patel, Ekta S ^a,b   Yu, Qing ^a,b  

^a FORSYTH INSTITUTE   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Exocrine gland; Inflammation; Interleukin 6; Sj gren's syndrome

Indexed keywords

CASPASE 3; CD3 ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN-6, MOUSE; NEUTRALIZING ANTIBODY; PROTEIN BCL X; RECOMBINANT PROTEIN; STAT3 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; ENZYME ACTIVATION; EXOCRINE GLAND; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INFLAMMATION; LACRIMAL GLAND; LEUKOCYTE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND; SERODIAGNOSIS; SJOEGREN SYNDROME; TREATMENT DURATION; UPREGULATION; ANIMAL; C57BL MOUSE; CELL LINE; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, NEUTRALIZING; APOPTOSIS; BCL-X PROTEIN; CASPASE 3; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; EXOCRINE GLANDS; FEMALE; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; MICE, INBRED C57BL; MICE, INBRED NOD; RECOMBINANT PROTEINS; SALIVARY GLANDS; SJOGREN'S SYNDROME; STAT3 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84943815399     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.07.027     Document Type: Article

References (62)

1. Neurath M.F., Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev 2011, 22:83-89.
2. Danese S., Gao B. Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut 2010, 59:149-151.
3. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006, 8(Suppl 2):S3.
4. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542.
5. Lindroos J., Svensson L., Norsgaard H., Lovato P., Moller K., Hagedorn P.H., et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J Invest Dermatol 2011, 131:1110-1118.
6. Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi Y., Nomura S., et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2008, 105:9041-9046.
7. Lee E.G., Mickle-Kawar B.M., Gallucci R.M. IL-6 deficiency exacerbates skin inflammation in a murine model of irritant dermatitis. J Immunot 2013, 10:192-200.
8. Balto K., Sasaki H., Stashenko P. Interleukin-6 deficiency increases inflammatory bone destruction. Infect Immun 2001, 69:744-750.
9. DiCosmo B.F., Picarella D., Flavell R.A. Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in non-obese diabetic mice. Int Immunol 1994, 6:1829-1837.
10. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
11. Sun R., Tian Z., Kulkarni S., Gao B. IL-6 prevents T cell-mediated hepatitis via inhibition of NKT cells in CD4+ T cell- and STAT3-dependent manners. J Immunol 2004, 172:5648-5655.
12. Samavedam U.K., Kalies K., Scheller J., Sadeghi H., Gupta Y., Jonkman M.F., et al. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun 2013, 40:74-85.
13. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
14. Steensberg A., Fischer C.P., Keller C., Moller K., Pedersen B.K. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am J Physiol Endocrinol Metab 2003, 285:E433-E437.
15. Jin J.O., Han X., Yu Q. Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun 2013, 40:28-44.
16. Jin X., Zimmers T.A., Zhang Z., Pierce R.H., Koniaris L.G. Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice. Gut 2010, 59:186-196.
17. Dann S.M., Spehlmann M.E., Hammond D.C., Iimura M., Hase K., Choi L.J., et al. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol 2008, 180:6816-6826.
18. Kida H., Yoshida M., Hoshino S., Inoue K., Yano Y., Yanagita M., et al. Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 2005, 288:L342-L349.
19. Ward N.S., Waxman A.B., Homer R.J., Mantell L.L., Einarsson O., Du Y., et al. Interleukin-6-induced protection in hyperoxic acute lung injury. Am J Respir Cell Mol Biol 2000, 22:535-542.
20. Chao K.C., Chao K.F., Chuang C.C., Liu S.H. Blockade of interleukin 6 accelerates acinar cell apoptosis and attenuates experimental acute pancreatitis in vivo. Br J Surg 2006, 93:332-338.
21. Fox P.C. Autoimmune diseases and Sjögren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007, 1098:15-21.
22. Mavragani C.P., Moutsopoulos H.M. Conventional therapy of Sjögren's syndrome. Clin Rev Allergy Immunol 2007, 32:284-291.
23. Segal B., Bowman S.J., Fox P.C., Vivino F.B., Murukutla N., Brodscholl J., et al. Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes 2009, 7:46.
24. Thanou-Stavraki A., James J.A. Primary Sjögren's syndrome: current and prospective therapies. Semin Arthritis Rheum 2008, 37:273-292.
25. Katsifis G.E., Moutsopoulos N.M., Wahl S.M. T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol 2007, 32:252-264.
26. Lee B.H., Tudares M.A., Nguyen C.Q. Sjögren's syndrome: an old tale with a new twist. Arch Immunol Ther Exp (Warsz) 2009, 57:57-66.
27. Nikolov N.P., Illei G.G. Pathogenesis of Sjögren's syndrome. Curr Opin Rheumatol 2009, 21:465-470.
28. Tobon G.J., Pers J.O., Youinou P., Saraux A. B cell-targeted therapies in Sjögren's syndrome. Autoimmun Rev 2010, 9:224-228.
29. Voulgarelis M., Tzioufas A.G. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol 2010, 6:529-537.
30. van Woerkom J.M., Kruize A.A., Wenting-van Wijk M.J., Knol E., Bihari I.C., Jacobs J.W., et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjögren's syndrome compared with non-Sjögren's sicca syndrome. Ann Rheum Dis 2005, 64:1474-1479.
31. Roescher N., Tak P.P., Illei G.G. Cytokines in Sjögren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010, 69:945-948.
32. Jin J.O., Yu Q. T Cell-Associated Cytokines in the Pathogenesis of Sjögren's Syndrome. J Clin Cell Immunol 2013, S!
33. Baker O.J., Camden J.M., Redman R.S., Jones J.E., Seye C.I., Erb L., et al. Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma alter tight junction structure and function in the rat parotid gland Par-C10 cell line. Am J Physiol Cell Physiol 2008, 295:C1191-C1201.
34. Odusanwo O., Chinthamani S., McCall A., Duffey M.E., Baker O.J. Resolvin D1 prevents TNF-alpha-mediated disruption of salivary epithelial formation. Am J Physiol Cell Physiol 2012, 302:C1331-C1345.
35. Pauley K.M., Gauna A.E., Grichtchenko I.I., Chan E.K., Cha S. A secretagogue-small interfering RNA conjugate confers resistance to cytotoxicity in a cell model of Sjögren's syndrome. Arthritis Rheum 2011, 63:3116-3125.
36. Kajiya M., Ichimonji I., Min C., Zhu T., Jin J.O., Yu Q., et al. Muscarinic type 3 receptor induces cytoprotective signaling in salivary gland cells through epidermal growth factor receptor transactivation. Mol Pharmacol 2012, 82:115-124.
37. Kamachi M., Kawakami A., Yamasaki S., Hida A., Nakashima T., Nakamura H., et al. Regulation of apoptotic cell death by cytokines in a human salivary gland cell line: distinct and synergistic mechanisms in apoptosis induced by tumor necrosis factor alpha and interferon gamma. J Lab Clin Med 2002, 139:13-19.
38. Ishimaru N., Arakaki R., Yoshida S., Yamada A., Noji S., Hayashi Y. Expression of the retinoblastoma protein RbAp48 in exocrine glands leads to Sjögren's syndrome-like autoimmune exocrinopathy. J Exp Med 2008, 205:2915-2927.
39. Ishimaru N., Arakaki R., Omotehara F., Yamada K., Mishima K., Saito I., et al. Novel role for RbAp48 in tissue-specific, estrogen deficiency-dependent apoptosis in the exocrine glands. Mol Cell Biol 2006, 26:2924-2935.
40. Okuma A., Hoshino K., Ohba T., Fukushi S., Aiba S., Akira S., et al. Enhanced apoptosis by disruption of the STAT3-IkappaB-zeta signaling pathway in epithelial cells induces Sjögren's syndrome-like autoimmune disease. Immunity 2013, 38:450-460.
41. Grisius M.M., Bermudez D.K., Fox P.C. Salivary and serum interleukin 6 in primary Sjögren's syndrome. J Rheumatol 1997, 24:1089-1091.
42. Hulkkonen J., Pertovaara M., Antonen J., Pasternack A., Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 2001, 40:656-661.
43. Ferran C., Sheehan K., Dy M., Schreiber R., Merite S., Landais P., et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990, 20:509-515.
44. Matthys P., Dillen C., Proost P., Heremans H., Van Damme J., Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol 1993, 23:2209-2216.
45. Leu C.M., Wong F.H., Chang C., Huang S.F., Hu C.P. Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 2003, 22:7809-7818.
46. Fahmi A., Smart N., Punn A., Jabr R., Marber M., Heads R. P42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cell Signal 2013, 25:898-909.
47. Dhillon A.S., Hagan S., Rath O., Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
48. Hideshima T., Nakamura N., Chauhan D., Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001, 20:5991-6000.
49. Jee S.H., Chiu H.C., Tsai T.F., Tsai W.L., Liao Y.H., Chu C.Y., et al. The phosphotidyl inositol 3-kinase/Akt signal pathway is involved in interleukin-6-mediated Mcl-1 upregulation and anti-apoptosis activity in basal cell carcinoma cells. J Invest Dermatol 2002, 119:1121-1127.
50. Kobayashi S., Werneburg N.W., Bronk S.F., Kaufmann S.H., Gores G.J. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005, 128:2054-2065.
51. Matsumura R., Umemiya K., Goto T., Nakazawa T., Ochiai K., Kagami M., et al. Interferon gamma and tumor necrosis factor alpha induce Fas expression and anti-Fas mediated apoptosis in a salivary ductal cell line. Clin Exp Rheumatol 2000, 18:311-318.
52. Saito I., Haruta K., Shimuta M., Inoue H., Sakurai H., Yamada K., et al. Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10. J Immunol 1999, 162:2488-2494.
53. Ishimaru N., Saegusa K., Yanagi K., Haneji N., Saito I., Hayashi Y. Estrogen deficiency accelerates autoimmune exocrinopathy in murine Sjögren's syndrome through fas-mediated apoptosis. Am J Pathol 1999, 155:173-181.
54. Manganelli P., Fietta P. Apoptosis and Sjögren syndrome. Semin Arthritis Rheum 2003, 33:49-65.
55. Bolstad A.I., Eiken H.G., Rosenlund B., Alarcon-Riquelme M.E., Jonsson R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum 2003, 48:174-185.
56. Jin J.O., Kawai T., Cha S., Yu Q. Interleukin-7 enhances the Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy in mice. Arthritis Rheum 2013, 65:2132-2142.
57. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
58. Ivanov I.I., Zhou L., Littman D.R. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 2007, 19:409-417.
59. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008, 58:734-743.
60. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
61. Kang K.Y., Kim H.O., Kwok S.K., Ju J.H., Park K.S., Sun D.I., et al. Impact of interleukin-21 in the pathogenesis of primary Sjögren's syndrome: increased serum levels of interleukin-21 and its expression in the labial salivary glands. Arthritis Res Ther 2011, 13:R179.
62. Stumhofer J.S., Silver J.S., Laurence A., Porrett P.M., Harris T.H., Turka L.A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007, 8:1363-1371.